What COVID-19 Vaccines Teach Us About All Tech Transfers

Source: Outsourced Pharma

Are there “lessons learned” and “best practices” from the COVID-19 vaccine efforts you can apply to tech transfers of your own projects – be they small molecule, biologics, or cell and gene therapies?

View the On-Demand version of OP-Virtual from our discussion on November 4, 2020 on what we’ve learned thus far, and how to “transfer” that knowledge to your projects.

Our panelists:

  • Bikash Chatterjee, CEO | Pharmatech Associates
  • David A. Dodd, Chairman, CEO | GeoVax
  • Marcelo Omelczuk, (former) VP, Global Pharmaceutical Technology and Launch Management | Allergan
  • Mark F. Witcher, Ph.D., (former) VP Manufacturing | Amgen & (former) SVP Operations | Covance
  • Louis Garguilo, Chief Editor | Outsourced Pharma

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma